Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

Joanie Pinard; Alisa N Femia; Michael Roman; Abeer Alsarheed; Cara Joyce; Janice Lin; Ruth Ann Vleugels

doi:10.1001/jamadermatol.2018.5215

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

JAMA Dermatol. 2019 Apr 1;155(4):494-496. doi: 10.1001/jamadermatol.2018.5215.

Authors

Joanie Pinard¹, Alisa N Femia², Michael Roman², Abeer Alsarheed¹, Cara Joyce³, Janice Lin^{1

4}, Ruth Ann Vleugels¹

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, New York University Ronald O. Perelman School of Medicine, New York.
³ Department of Public Health Sciences, Loyola University, Chicago, Illinois.
⁴ Division of Immunology & Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.

Abstract

This study investigates the use of systemic treatment for clinically amyopathic dermatomyositis using natural language queries and ICD codes for amyopathic and hypomyopathic dermatomyositis.

Publication types

Comparative Study
Multicenter Study

MeSH terms

Administration, Oral
Administration, Topical
Adult
Aged
Antimalarials / therapeutic use*
Dermatologic Agents / administration & dosage*
Dermatomyositis / drug therapy*
Dermatomyositis / pathology*
Female
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
Severity of Illness Index
Statistics, Nonparametric
Tertiary Care Centers
Treatment Outcome
United States

Substances

Antimalarials
Dermatologic Agents

Supplementary concepts

Amyopathic dermatomyositis